[go: up one dir, main page]

FI20126281L - Temotsolomidin polymeeripartikkelipohjainen annosmuoto pahanlaatuisten kasvainten hoitoon - Google Patents

Temotsolomidin polymeeripartikkelipohjainen annosmuoto pahanlaatuisten kasvainten hoitoon Download PDF

Info

Publication number
FI20126281L
FI20126281L FI20126281A FI20126281A FI20126281L FI 20126281 L FI20126281 L FI 20126281L FI 20126281 A FI20126281 A FI 20126281A FI 20126281 A FI20126281 A FI 20126281A FI 20126281 L FI20126281 L FI 20126281L
Authority
FI
Finland
Prior art keywords
temozolomide
treatment
dosage form
polymer particle
malignant tumors
Prior art date
Application number
FI20126281A
Other languages
English (en)
Swedish (sv)
Other versions
FI20126281A7 (fi
Inventor
Ekaterina Vasilenko
Evgeny Vorontsov
Evgenij Severin
Victor Gulenko
Maxim Mitrokhin
Original Assignee
Filana Ltd Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Filana Ltd Oy filed Critical Filana Ltd Oy
Priority to FI20126281A priority Critical patent/FI20126281L/fi
Priority to US14/650,799 priority patent/US20150328169A1/en
Priority to EA201591111A priority patent/EA201591111A1/ru
Priority to PCT/FI2013/051151 priority patent/WO2014091078A1/en
Publication of FI20126281A7 publication Critical patent/FI20126281A7/fi
Publication of FI20126281L publication Critical patent/FI20126281L/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5146Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/02Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
    • C08G63/06Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxycarboxylic acids
    • C08G63/08Lactones or lactides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
FI20126281A 2012-12-10 2012-12-10 Temotsolomidin polymeeripartikkelipohjainen annosmuoto pahanlaatuisten kasvainten hoitoon FI20126281L (fi)

Priority Applications (4)

Application Number Priority Date Filing Date Title
FI20126281A FI20126281L (fi) 2012-12-10 2012-12-10 Temotsolomidin polymeeripartikkelipohjainen annosmuoto pahanlaatuisten kasvainten hoitoon
US14/650,799 US20150328169A1 (en) 2012-12-10 2013-12-10 Polymeric particles-based temozolomide dosage form
EA201591111A EA201591111A1 (ru) 2012-12-10 2013-12-10 Лекарственная дозированная форма, состоящая из полимерных частиц темозоломида
PCT/FI2013/051151 WO2014091078A1 (en) 2012-12-10 2013-12-10 Polymeric particles-based temozolomide dosage form

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20126281A FI20126281L (fi) 2012-12-10 2012-12-10 Temotsolomidin polymeeripartikkelipohjainen annosmuoto pahanlaatuisten kasvainten hoitoon

Publications (2)

Publication Number Publication Date
FI20126281A7 FI20126281A7 (fi) 2014-06-11
FI20126281L true FI20126281L (fi) 2014-06-11

Family

ID=50933803

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20126281A FI20126281L (fi) 2012-12-10 2012-12-10 Temotsolomidin polymeeripartikkelipohjainen annosmuoto pahanlaatuisten kasvainten hoitoon

Country Status (4)

Country Link
US (1) US20150328169A1 (fi)
EA (1) EA201591111A1 (fi)
FI (1) FI20126281L (fi)
WO (1) WO2014091078A1 (fi)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933078B2 (en) 2011-07-14 2015-01-13 Research Cancer Institute Of America Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances
US11890292B2 (en) 2017-02-27 2024-02-06 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
US11369585B2 (en) 2017-03-17 2022-06-28 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
WO2019071229A1 (en) 2017-10-06 2019-04-11 Research Cancer Institute Of America COMPOSITIONS, METHODS, SYSTEMS AND / OR KITS FOR PREVENTING AND / OR TREATING NEOPLASMS
EP3710434A4 (en) 2017-11-17 2021-07-28 Research Cancer Institute of America COMPOSITIONS, METHODS, SYSTEMS AND / OR KITS FOR THE PREVENTION AND / OR TREATMENT OF NEOPLASMS
CN116262099B (zh) * 2022-08-16 2025-10-31 中国人民解放军军事科学院军事医学研究院 一种缓释温敏凝胶及其制备方法和其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2631714C (en) * 2005-12-02 2014-09-16 Novartis Ag Nanoparticles for use in immunogenic compositions
US10555911B2 (en) * 2012-05-04 2020-02-11 Yale University Highly penetrative nanocarriers for treatment of CNS disease
EP2662079A1 (en) * 2012-05-10 2013-11-13 Ordway Research Institute, Inc. Uses of formulations of thyroid hormone antagonists and nanoparticulate forms thereof to increase chemosensivity and radiosensitivity in tumor or cancer cells

Also Published As

Publication number Publication date
US20150328169A1 (en) 2015-11-19
WO2014091078A1 (en) 2014-06-19
FI20126281A7 (fi) 2014-06-11
EA201591111A1 (ru) 2016-04-29

Similar Documents

Publication Publication Date Title
IL289300A (en) Combination therapy for treating cancer
IL274318A (en) Cancer treatment with rapamycin target site kinase inhibitors
IL264901B (en) Administration of kynurenine depleting enzymes for tumor therapy
HUE047198T2 (hu) Fitokannabinoidok emlõrák kezelésére
IL241232B (en) Cancer treatment agents
HUE048876T2 (hu) Rákos megbetegedések kezelése
PL2739153T3 (pl) Leczenie raka sutka
EP2968348A4 (en) COMPOUNDS FOR THE TREATMENT OF CANCER
EP2968343A4 (en) COMBINATION THERAPY FOR THE TREATMENT OF CANCER
HRP20190046T1 (hr) Kombinirana terapija za liječenje raka
IL234639B (en) Cancer treatment with rapamycin target site kinase inhibitors
ZA201406706B (en) Treatment of cancer with tor kinase inhibitors
IL234641A0 (en) Cancer treatment with rapamycin target site kinase inhibitors
LT2914254T (lt) Kombinacinės terapijos chemoresistencinių vėžių gydymui
HRP20180670T1 (hr) Novi postupak dobivanja spojeva namijenjenih upotrebi u liječenju raka
KR102082363B9 (ko) 난소암의 치료를 위한 조합 치료
EP2903644A4 (en) TREATMENT OF CANCER
FI20126281L (fi) Temotsolomidin polymeeripartikkelipohjainen annosmuoto pahanlaatuisten kasvainten hoitoon
DK2802351T3 (da) Midler til behandling af triple-negativ brystkræft
GB201217892D0 (en) Treatment of cancer
HUE049301T2 (hu) Kurkofenol-vegyület rák kezelésére
EP2886122A4 (en) MEDICINE FOR THE TREATMENT OF CANCER
EP2817286A4 (en) KINASEHEMMER FOR THE TREATMENT OF CANCER
PL2855475T3 (pl) Alfa-karboliny do leczenia nowotworu
GB201214877D0 (en) Compounds for treatments of tumors

Legal Events

Date Code Title Description
MM Patent lapsed